ClinicalTrials.gg
CompletedNCT02039505Updated Apr 25, 2019Results posted

Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis

A Phase 3 interventional study of Vedolizumab and Vedolizumab placebo in Ulcerative Colitis, sponsored by Takeda. Completed at 59 sites in Japan. Open to participants aged 15 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-04-25.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
292
Allocation
Randomized
Ages
15 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies testing vedolizumab in Colitis, Ulcerative — 5 open to participants now, 9 under way, 6 of them phase 3. vedolizumab · Colitis, Ulcerative.

Enrollment
11th of 38
292 · median 110
Started
2014
with 1 other
Phase 3
14 of 38
3 open now
Registered
5th of 38
by date
Lead sponsor
22 of 38
Takeda

Among the 38 studies testing vedolizumab in Colitis, Ulcerative, this one is the 11th largest by enrollment, is one of 2 that started in 2014, is one of 14 in phase 3, and was the 5th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

5 of the 38 studies testing vedolizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About vedolizumab

vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 15 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing vedolizumab in Colitis, Ulcerative, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate efficacy, safety and pharmacokinetics of the vedolizumab (MLN0002) induction and maintenance therapy in Japanese participants with moderate or severe ulcerative colitis (UC).

Read the detailed description

This study is a phase 3, multicenter, randomized, double-blinded, placebo-controlled, parallel-group study to examine the efficacy, safety, and pharmacokinetics of MLN0002 (Vedolizumab) in induction and maintenance therapy in Japanese patients with moderately or severely active ulcerative colitis.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
15 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In the opinion of the investigator, a participant is capable of understanding and complying with protocol requirements.
  2. A participant who is capable of entering the signature and the date on the by himself/herself or by the participant's legally acceptable representative, if applicable, prior to initiation of study procedures.
  3. A participant aged 15 to 80 (inclusive) at the time of signing the informed consent (regardless of sexes).
  4. A male participant, who has no sterilization history and whose female partner has , who agreed with taking proper during the period from the time of signing the informed consent form through 6 months after the last dose of study drug.
  5. A female participant with child-bearing potential (having no history of sterilization or whose last menstruation was within 2 years) whose male partner is not receiving contraceptive treatment, and agreed to take proper contraception during the period from the time of signing on the informed consent form through 6 months after the last dose of the study drug.
  6. Participants with diagnosis of total or left-sided ulcerative colitis (UC) based on the Revised Diagnostic Criteria for UC issued by "Research Group for Intractable Inflammatory Bowel Disease Designated as Specified Disease" by the Ministry of Health, Labor and Welfare (MHLW) of Japan (2012) at least 6 months before the start of administration of the study drug.
  7. A participant with moderately or severely active UC as determined by baseline complete Mayo score of 6 to 12 (inclusive) with an endoscopic subscore of ≥2.
  8. Participants whose complication of colon cancer or dysplasia had to be ruled out by total colonoscopy at the start of the study drug administration (or the results from total colonoscopy performed within 1 year before giving consent are available), if participants met any of the following criteria; participants with ≥8-year history of total or left-sided colitis, participants aged ≥50 years, or participants with a first-degree family history of colon cancer.
  9. Participants meeting the following treatment failure criteria with at least one of the following agents within 5 years before signing on the informed consent:

      • Resistance: Participants whose response was inadequate after treatment of ≥40 mg/day for ≥1 week (oral or IV) or 30 to 40 mg/day for ≥2 weeks (oral or IV).
      • Dependence: Participants for which it is difficult to reduce the dosage to \<10 mg/day due to recurrence during gradual dose reduction (oral or IV).
      • Intolerance: Participants who were unable to receive continuous treatment due to adverse reactions (e.g., Cushing's syndrome, osteopenia/osteoporosis, hyperglycaemia, insomnia, infection).
    1. Immunomodulators (azathioprine [AZA] or 6- mercaptopurine [6-MP])

      • : Participants whose response was inadequate after treatment for ≥12 weeks.
      • Intolerance: Participants who were unable to receive continuous treatment due to adverse reactions (e.g., nausea/vomiting, abdominal pain, pancreatitis, liver function test abnormalities, lymphopenia, thiopurine S-methyltransferase genetic mutation, infection).
    2. Tumor necrosis factor-alpha (TNFα) antagonist

      • Inadequate response: Participants whose response was inadequate after the induction therapy in the dosage described in the package insert.
      • Loss of response: Participants who had recurrence during the scheduled maintenance therapy after achievement of clinical response (those who withdrew for other reasons than relapse are not applicable here).
      • Intolerance: Participants who were unable to receive continuous treatment due to adverse reactions (eg, infusion-related reaction, demyelination, congestive heart failure, infection).

Exclusion criteria

Exclusion Criteria:

  1. Participants whose partial Mayo score decrease by 3 points or more between screening and the start of study drug administration.
  2. Participants having or suspected to have abdominal abscess or toxic megacolon.
  3. Participants with a history of subtotal or total colectomy.
  4. Participants with ileostomy, colostomy, fistula or severe intestinal stenosis.
  5. Participants having a treatment history with natalizumab, efalizumab or rituximab.
  6. Participants who started oral 5-ASA, probiotics, or oral (≤30 mg/day) within 13 days before the first dose of the study drug. Participants who have used these drugs for at least 14 days before the first dose of the study drug, and who changed dosage of or discontinued these drugs within 13 days before the first dose of the study drug.
  7. Participants who have received 5-ASA, corticosteroid enemas/suppositories, corticosteroid IV infusion, oral corticosteroid at >30 mg/day, drugs for diarrhea-predominant irritable bowel syndrome, or Chinese herbal medicine for the UC treatment (eg, Daikenchuto) within 13 days before the first dose of the study drug.
  8. Participants who have used an antidiarrheal drug for 4 or more consecutive days within 13 days before the first dose of the study drug or within 7 days before the first dose of the study drug.
  9. Participants who have received AZA or 6-MP within 27 days before the first dose of the study drug However, this will not apply to participants who have used these drugs for 83 or more days before the first dose of the study drug and continued the steady dose administration of the drugs for 27 or more days before the first dose of the study drug.
  10. Participants who have received cyclosporine, tacrolimus, methotrexate, tofacitinib or any study drugs of low-molecular compound for UC treatment within 27 days before the first dose of the study drug.
  11. Participants who have received adalimumab within 27 days before the first dose of the study drug or any biologic agents other than adalimumab within 55 days before the first dose of the study drug. However, this will not apply to participants who have topically received these drugs (eg., intraocular injection for treatment of age-related macular degeneration).
  12. Participants who have received any live-vaccinations within 27 days before the first dose of the study drug.
  13. Participants who underwent the enterectomy within 27 days before the first dose of the study drug or those anticipated to require an enterectomy during the study.
  14. Participants who have received leukocytapheresis or granulocyte apheresis within 27 days before the first dose of the study drug.
  15. Participants who have been infected with an intestinal pathogen including clostridium difficile or cytomegalovirus within 27 days before the first dose of the study drug.
  16. Participants with evidence of adenomatous colonic polyps that need to be removed at the start of study drug administration.
  17. Participants with a history or a complication of colonic mucosal dysplasia.
  18. Participants suspected to have enteritis other than UC.
  19. Participants indicated in the screening test as surface (HBs) antigen-positive or virus (HCV) antibody-positive. Participants indicated as hepatitis B core (HBc) antibody-positive or HBs antibody positive even though HBs antigen-negative However, the criteria will not apply to those with only HBs antibody-positive due to hepatitis B virus (HBV) vaccination, HBV-DNA-negative, HCV antigen-negative or HCV-RNA-negative.
  20. Participants who have or are suspected to have a history of tuberculosis (including those whose findings in the chest imaging procedure at screening showing anamnesis of tuberculosis). However, the criteria will not apply to those who had completed prophylactic treatment with isoniazid, and who have been receiving prophylactic isoniazid for 21 days or longer before the first dose of the study drug (the latter may initiate study drug administration with screening phase extended to 28 days at maximum for prophylactic treatment to become 21 days or more).
  21. Participants indicated as positive in T-SPOT or QuantiFERON at screening test.
  22. Participants who have a history or complication of identified congenital or acquired immunodeficiency syndrome (eg, not-classifiable immunodeficiency, [HIV] infection or organ transplantation).
  23. Participants who were affected by extra-intestinal infection (eg, pneumonia, sepsis, active hepatitis or pyelonephritis) within 27 days before the first dose of the study drug.
  24. Participants who have treatment history with MLN0002.
  25. Nursing mothers during the screening phase, or female participants indicated positive in urine pregnancy test either at the screening or baseline.
  26. Participants having serious complications in the heart, lung, liver, kidney, metabolism, gastrointestinal system, urinary system, endocrine system or blood.
  27. Participants with a history of an operation requiring general anesthesia within 27 days before the first dose of the study drug, or with a schedule of an operation requiring hospitalization during the study period.
  28. Participants having a complication or a history of However, it will not apply to the following participants;

    • Participants who had a curative resection of localized skin basal cell carcinoma or had completed curative radiotherapy.
    • Participants who have not experienced recurrence for 1 year or longer since completion of curative resection or curative radiotherapy for skin squamous cell carcinoma.
    • Participants who have not experienced recurrence for 3 year or longer since completion of curative resection or curative radiotherapy for intraepithelial carcinoma of uterine cervix.

    For participants having a substantially distant history of malignancy (eg, 10 years or longer without recurrence since treatment completion), the Investigator and the sponsor will discuss to decide eligibility on the basis of type of malignancy and treatment applied.

  29. Participants having a history or a complication of the central nervous disorder, including stroke, multiple sclerosis, brain tumor, or neurodegenerative disease.
  30. Participants for which any subjective symptoms in the Subjective PML checklist were found at the screening or baseline.
  31. Participants for which any of the following laboratory abnormalities were found at the screening;

    • ≤8 g/dL
    • White blood cells ≤3,000/μL
    • Lymphocytes ≤500/μL
    • ≤100,000/μL, or ≥1,200,000/μL
    • (ALT) or aspartate aminotransferase (AST) ≥3× (ULN)
    • Alkaline phosphatase (ALP) ≥3×ULN
    • Creatinine ≥2×ULN
  32. Participants having a history or a complication of alcohol dependence or illicit drug use within one year before the first dose of the study drug.
  33. Participants having a history or a complication of psychotic disorder that may obstruct compliance with the study procedures.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
292 participants (actual)

Study arms

  • Placebo comparator
    Induction Phase: Cohort 1, Placebo

    Vedolizumab placebo-matching, intravenous (IV) infusion, once at Weeks 0, 2 and 6 in the induction phase.

    Drug: Vedolizumab placebo

  • Experimental
    Induction Phase: Cohort 1, Vedolizumab 300 mg

    Vedolizumab 300 mg, IV infusion, once at Weeks 0, 2, and 6 in the induction phase.

    Drug: Vedolizumab

  • Experimental
    Induction Phase: Cohort 2, Vedolizumab 300 mg

    Vedolizumab 300 mg, IV infusion, once at Weeks 0, 2 and 6 in the induction phase.

    Drug: Vedolizumab

  • Experimental
    Maintenance Phase: Placebo

    Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab in induction phase and achieved clinical response at Week 10 and were randomized to receive placebo in maintenance phase.

    Drug: Vedolizumab · Drug: Vedolizumab placebo

  • Experimental
    Maintenance Phase: Vedolizumab 300 mg

    Vedolizumab 300 mg, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab in induction phase and achieved clinical response at Week 10 and were randomized to receive vedolizumab in maintenance phase.

    Drug: Vedolizumab

  • Placebo comparator
    Maintenance Phase: Placebo continuation

    Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab placebo-matching in induction phase and achieved clinical response at Week 10 received placebo in maintenance phase without randomization.

    Drug: Vedolizumab placebo

  • Experimental
    Open-Label Cohort: Vedolizumab 300 mg

    Vedolizumab 300 mg, IV infusion, once at Weeks 0, 2 and 6 and then every 8 weeks thereafter up to Week 94 in open-label cohort.

    Drug: Vedolizumab

Interventions

  • Vedolizumab intravenous infusion

    Also known as: MLN0002

  • DrugVedolizumab placebo

    Vedolizumab placebo

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Clinical Response at Week 10 in Induction Phase

    Clinical response is defined as a reduction in complete Mayo score of ≥3 points and ≥30% from Baseline with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point. Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores (rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment), a global assessment by the physician, and an endoscopic subscore. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).

    Time frame: Week 10

  2. Percentage of Participants With Clinical Remission at Week 60 in Maintenance Phase

    Clinical Remission is defined as a complete Mayo score of ≤2 points and no individual subscore \>1 point. Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).

    Time frame: Week 60

  3. Number of Participants Who Experienced at Least One or More Treatment-Emergent Adverse Events (TEAEs)

    An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.

    Time frame: From Baseline to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)

  4. Number of Participants With TEAE Related to Body Weight

    Time frame: From Baseline to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)

  5. Number of Participants With TEAE Related to Vital Signs

    Vital signs included body temperature (axilla), sitting blood pressure (after the participant has rested for at least 5 minutes), and pulse (bpm).

    Time frame: From Baseline to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)

  6. Number of Participants With TEAE Related to Electrocardiogram (ECG)

    Time frame: From Baseline to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)

  7. Number of Participants With Markedly Abnormal Laboratory Parameters Values

    The laboratory values outside the range (Hemoglobin \<=7 g/dL, Lymphocytes \<500 /µL, WBC \<2000 /µL, Platelets \<7.5 10\^4/µL, Neutrophils \<1000 /µL, alanine aminotransferase (ALT) \>3.0 U/L x upper limit of normal (ULN), aspartate aminotransferase (AST) \>3.0 U/L x ULN, Total Bilirubin \>2.0 mg/dL x ULN, Amylase \>2.0 (U/L) x ULN were considered markedly abnormal. Only laboratory parameters with events were represented.

    Time frame: From Baseline to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)

Secondary outcomes

  1. Percentage of Participants With Clinical Remission at Week 10 in Induction Phase

    Clinical Remission is defined as a complete Mayo score of ≤2 points and no individual subscore \>1 point. Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).

    Time frame: Week 10

  2. Percentage of Participants With Mucosal Healing at Week 10 in Induction Phase

    Mucosal healing is defined as a Mayo endoscopic subscore of ≤1 point. Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Endoscopic findings were scored on a scale from 0 to 3 as follows: 0=Normal or inactive disease; 1=Mild disease (erythema, decreased vascular pattern, mild friability); 2=Moderate disease (marked erythema, lack of vascular pattern, friability, erosions); 3=Severe disease (spontaneous bleeding, ulceration).

    Time frame: Week 10

  3. Percentage of Participants With Durable Clinical Response in Maintenance Phase

    Durable clinical response is defined as reduction in complete Mayo score of ≥3 points and ≥30% from Baseline (Week 0) with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point at both Weeks 10 and 60. Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).

    Time frame: Weeks 10 and 60

  4. Percentage of Participants With Mucosal Healing at Week 60 in Maintenance Phase

    Mucosal healing is defined as a Mayo endoscopic subscore of ≤1 point. Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Endoscopic findings were scored on a scale from 0 to 3 as follows: 0=Normal or inactive disease; 1=Mild disease (erythema, decreased vascular pattern, mild friability); 2=Moderate disease (marked erythema, lack of vascular pattern, friability, erosions); 3=Severe disease (spontaneous bleeding, ulceration).

    Time frame: Week 60

  5. Percentage of Participants With Durable Remission in Maintenance Phase

    Durable clinical remission is defined as complete Mayo score of ≤2 points and no individual subscore \>1 point at both Weeks 10 and 60. Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).

    Time frame: Weeks 10 and 60

  6. Percentage of Participants With Corticosteroid-Free Remission at Week 60 in Maintenance Phase

    Clinical Remission is defined as a complete Mayo score of ≤2 points and no individual subscore \>1 point. Corticosteroid-free clinical remission is defined as participants using oral corticosteroids at baseline (Week 0) who discontinued corticosteroids and were in clinical remission at Week 60. Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).

    Time frame: Week 60

  7. Serum Vedolizumab Concentration in Induction Phase

    Time frame: Pre-dose at Weeks 2, 6, 10 and 14

  8. Serum Vedolizumab Concentration in Maintenance Phase

    Time frame: Pre-dose at Weeks 2, 6, 10, 14, 22, 30 and 60

  9. Number of Participants With Anti-vedolizumab Antibodies (AVA) in Induction Phase

    Blood samples were collected and tested for serum concentration of anti-vedolizumab antibodies in a laboratory by means of electrochemoluminescent (ECL) assay.

    Time frame: Weeks 0, 10 and 16 weeks after the last dose of study drug (Up to approximately 170 weeks)

  10. Number of Participants With Anti-vedolizumab Antibodies (AVA) in Maintenance Phase

    Blood samples were collected and tested for serum concentration of anti-vedolizumab antibodies in a laboratory by means of ECL assay.

    Time frame: Weeks 0, 10, 30, 60 and 16 weeks after the last dose of study drug (Up to approximately 170 weeks)

  11. Number of Participants With Neutralizing Anti-vedolizumab Antibodies (AVA) in Induction Phase

    Blood samples were collected, and serum neutralizing AVA was determined only for the AVA-positive samples in a laboratory by means of ECL assay.

    Time frame: Weeks 0, 10 and 16 weeks after the last dose of study drug (Up to approximately 170 weeks)

  12. Number of Participants With Neutralizing Anti-vedolizumab Antibodies (AVA) in Maintenance Phase

    Blood samples were collected, and serum neutralizing AVA was determined only for the AVA-positive samples in a laboratory by means of ECL assay.

    Time frame: Weeks 0, 10, 30, 60 and 16 weeks after the last dose of study drug (Up to approximately 170 weeks)

07

Results

Posted Mar 20, 2019

Participant flow

Participants took part in the study at 86 investigative sites in Japan from 04 February 2014 to 28 June 2018.

Induction Phase (Week 0 to Week 14)
Participant flow — Induction Phase (Week 0 to Week 14)
MilestoneInduction Phase: Cohort 1, PlaceboInduction Phase: Cohort 1, Vedolizumab 300 mgInduction Phase: Cohort 2, Vedolizumab 300 mgMaintenance Phase: PlaceboMaintenance Phase: Vedolizumab 300 mgMaintenance Phase: Placebo ContinuationOpen-Label Cohort: Vedolizumab 300 mg
Started82164460000
Completed78155360000
Not completed49100000
Withdrew: Pretreatment event/adverse event2870000
Withdrew: Lack of efficacy1130000
Withdrew: Major protocol deviation1000000
Maintenance Phase (Week 14 to Week 60)
Participant flow — Maintenance Phase (Week 14 to Week 60)
MilestoneInduction Phase: Cohort 1, PlaceboInduction Phase: Cohort 1, Vedolizumab 300 mgInduction Phase: Cohort 2, Vedolizumab 300 mgMaintenance Phase: PlaceboMaintenance Phase: Vedolizumab 300 mgMaintenance Phase: Placebo ContinuationOpen-Label Cohort: Vedolizumab 300 mg
Started0004241260
Completed0001830120
Not completed0002411140
Withdrew: Lack of efficacy000138120
Withdrew: Pretreatment event/adverse event0006110
Withdrew: Voluntary withdrawal0003210
Withdrew: Pregnancy0002000
Open-Label (Week 10 up to Week 154)
Participant flow — Open-Label (Week 10 up to Week 154)
MilestoneInduction Phase: Cohort 1, PlaceboInduction Phase: Cohort 1, Vedolizumab 300 mgInduction Phase: Cohort 2, Vedolizumab 300 mgMaintenance Phase: PlaceboMaintenance Phase: Vedolizumab 300 mgMaintenance Phase: Placebo ContinuationOpen-Label Cohort: Vedolizumab 300 mg
Started000000259
Completed000000188
Not completed00000071
Withdrew: Lack of efficacy00000044
Withdrew: Pretreatment event/adverse event00000019
Withdrew: Voluntary withdrawal0000007
Withdrew: Major protocol deviation0000001

Outcome measures

PrimaryPercentage of Participants With a Clinical Response at Week 10 in Induction Phase

Clinical response is defined as a reduction in complete Mayo score of ≥3 points and ≥30% from Baseline with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point. Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores (rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment), a global assessment by the physician, and an endoscopic subscore. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).

Time frame:
Week 10
Reported as:
Number · percentage of participants
Percentage of Participants With a Clinical Response at Week 10 in Induction Phase
percentage of participantsInduction Phase: Cohort 1, PlaceboInduction Phase: Cohort 1, Vedolizumab 300 mg
Percentage of Participants With a Clinical Response at Week 10 in Induction Phase32.9 (22.942 to 44.186)39.6 (32.093 to 47.557)
Statistical analysis
  • Induction Phase: Cohort 1, Placebo vs Induction Phase: Cohort 1, Vedolizumab 300 mg · Cochran-Mantel-Haenszel · p = 0.2722 · Adjusted odds ratio: 1.37 · 95% CI 0.779 to 2.399Cochran-Mantel-Haenszel (CMH) test was used for analysis. Prior tumor necrosis factor alpha (TNFα) antagonist use (yes/no) was used as stratification factor.
PrimaryPercentage of Participants With Clinical Remission at Week 60 in Maintenance Phase

Clinical Remission is defined as a complete Mayo score of ≤2 points and no individual subscore \>1 point. Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).

Time frame:
Week 60
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Remission at Week 60 in Maintenance Phase
percentage of participantsMaintenance Phase: PlaceboMaintenance Phase: Vedolizumab 300 mg
Percentage of Participants With Clinical Remission at Week 60 in Maintenance Phase31.0 (17.622 to 47.086)56.1 (39.750 to 71.531)
Statistical analysis
  • Maintenance Phase: Placebo vs Maintenance Phase: Vedolizumab 300 mg · Cochran-Mantel-Haenszel · p = 0.0210 · Adjusted odds ratio: 2.88 · 95% CI 1.168 to 7.108CMH test was used for analysis. Prior TNFα antagonist use (yes/no) was used as stratification factor.
PrimaryNumber of Participants Who Experienced at Least One or More Treatment-Emergent Adverse Events (TEAEs)

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.

Time frame:
From Baseline to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)
Reported as:
Count of participants · Participants
Number of Participants Who Experienced at Least One or More Treatment-Emergent Adverse Events (TEAEs)
ParticipantsInduction Phase: Cohort 1, PlaceboInduction Phase: Cohort 1, Vedolizumab 300 mgInduction Phase: Cohort 2, Vedolizumab 300 mgMaintenance Phase: PlaceboMaintenance Phase: Vedolizumab 300 mgMaintenance Phase: Placebo ContinuationOpen-Label Cohort: Vedolizumab 300 mg
Number of Participants Who Experienced at Least One or More Treatment-Emergent Adverse Events (TEAEs)438233333618241
PrimaryNumber of Participants With TEAE Related to Body Weight
Time frame:
From Baseline to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)
Reported as:
Count of participants · Participants
Number of Participants With TEAE Related to Body Weight
ParticipantsInduction Phase: Cohort 1, PlaceboInduction Phase: Cohort 1, Vedolizumab 300 mgInduction Phase: Cohort 2, Vedolizumab 300 mgMaintenance Phase: PlaceboMaintenance Phase: Vedolizumab 300 mgMaintenance Phase: Placebo ContinuationOpen-Label Cohort: Vedolizumab 300 mg
Number of Participants With TEAE Related to Body Weight0000000
PrimaryNumber of Participants With TEAE Related to Vital Signs

Vital signs included body temperature (axilla), sitting blood pressure (after the participant has rested for at least 5 minutes), and pulse (bpm).

Time frame:
From Baseline to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)
Reported as:
Count of participants · Participants
Number of Participants With TEAE Related to Vital Signs
ParticipantsInduction Phase: Cohort 1, PlaceboInduction Phase: Cohort 1, Vedolizumab 300 mgInduction Phase: Cohort 2, Vedolizumab 300 mgMaintenance Phase: PlaceboMaintenance Phase: Vedolizumab 300 mgMaintenance Phase: Placebo ContinuationOpen-Label Cohort: Vedolizumab 300 mg
Number of Participants With TEAE Related to Vital Signs25322024
PrimaryNumber of Participants With TEAE Related to Electrocardiogram (ECG)
Time frame:
From Baseline to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)
Reported as:
Count of participants · Participants
Number of Participants With TEAE Related to Electrocardiogram (ECG)
ParticipantsInduction Phase: Cohort 1, PlaceboInduction Phase: Cohort 1, Vedolizumab 300 mgInduction Phase: Cohort 2, Vedolizumab 300 mgMaintenance Phase: PlaceboMaintenance Phase: Vedolizumab 300 mgMaintenance Phase: Placebo ContinuationOpen-Label Cohort: Vedolizumab 300 mg
Number of Participants With TEAE Related to Electrocardiogram (ECG)1100011
PrimaryNumber of Participants With Markedly Abnormal Laboratory Parameters Values

The laboratory values outside the range (Hemoglobin \<=7 g/dL, Lymphocytes \<500 /µL, WBC \<2000 /µL, Platelets \<7.5 10\^4/µL, Neutrophils \<1000 /µL, alanine aminotransferase (ALT) \>3.0 U/L x upper limit of normal (ULN), aspartate aminotransferase (AST) \>3.0 U/L x ULN, Total Bilirubin \>2.0 mg/dL x ULN, Amylase \>2.0 (U/L) x ULN were considered markedly abnormal. Only laboratory parameters with events were represented.

Time frame:
From Baseline to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Markedly Abnormal Laboratory Parameters Values
ParticipantsInduction Phase: Cohort 1, PlaceboInduction Phase: Cohort 1, Vedolizumab 300 mgInduction Phase: Cohort 2, Vedolizumab 300 mgMaintenance Phase: PlaceboMaintenance Phase: Vedolizumab 300 mgMaintenance Phase: Placebo ContinuationOpen-Label Cohort: Vedolizumab 300 mg
Hemoglobin (g/dL) <=71410006
Lymphocytes (/µL) <50062210120
White Blood Cell (WBC) (/µL) <20000010000
Neutrophils (/µL) <10001111004
Alanine Aminotransferase (ALT) (U/L) >3.0 x ULN1001004
Aspartate Aminotransferase (AST) (U/L) >3.0 x ULN1001002
Total Bilirubin (mg/dL) >2.0 x ULN0200001
Amylase (U/L) >2.0 x ULN1210004
SecondaryPercentage of Participants With Clinical Remission at Week 10 in Induction Phase

Clinical Remission is defined as a complete Mayo score of ≤2 points and no individual subscore \>1 point. Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).

Time frame:
Week 10
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Remission at Week 10 in Induction Phase
percentage of participantsInduction Phase: Cohort 1, PlaceboInduction Phase: Cohort 1, Vedolizumab 300 mg
Percentage of Participants With Clinical Remission at Week 10 in Induction Phase12.2 (6.006 to 21.286)18.3 (12.695 to 25.072)
Statistical analysis
  • Induction Phase: Cohort 1, Placebo vs Induction Phase: Cohort 1, Vedolizumab 300 mg · Cochran-Mantel-Haenszel · p = 0.1980 · Adjusted odds ratio: 1.66 · 95% CI 0.762 to 3.596CMH test was used for analysis. Prior TNFα antagonist use (yes/no) was used as stratification factor.
SecondaryPercentage of Participants With Mucosal Healing at Week 10 in Induction Phase

Mucosal healing is defined as a Mayo endoscopic subscore of ≤1 point. Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Endoscopic findings were scored on a scale from 0 to 3 as follows: 0=Normal or inactive disease; 1=Mild disease (erythema, decreased vascular pattern, mild friability); 2=Moderate disease (marked erythema, lack of vascular pattern, friability, erosions); 3=Severe disease (spontaneous bleeding, ulceration).

Time frame:
Week 10
Reported as:
Number · percentage of participants
Percentage of Participants With Mucosal Healing at Week 10 in Induction Phase
percentage of participantsInduction Phase: Cohort 1, PlaceboInduction Phase: Cohort 1, Vedolizumab 300 mg
Percentage of Participants With Mucosal Healing at Week 10 in Induction Phase30.5 (20.796 to 41.638)36.6 (29.213 to 44.452)
Statistical analysis
  • Induction Phase: Cohort 1, Placebo vs Induction Phase: Cohort 1, Vedolizumab 300 mg · Cochran-Mantel-Haenszel · p = 0.3168 · Adjusted odds ratio: 1.33 · 95% CI 0.755 to 2.356CMH test was used for analysis. Prior TNFα antagonist use (yes/no) was used as stratification factor.
SecondaryPercentage of Participants With Durable Clinical Response in Maintenance Phase

Durable clinical response is defined as reduction in complete Mayo score of ≥3 points and ≥30% from Baseline (Week 0) with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point at both Weeks 10 and 60. Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).

Time frame:
Weeks 10 and 60
Reported as:
Number · percentage of participants
Percentage of Participants With Durable Clinical Response in Maintenance Phase
percentage of participantsMaintenance Phase: PlaceboMaintenance Phase: Vedolizumab 300 mg
Percentage of Participants With Durable Clinical Response in Maintenance Phase35.7 (21.551 to 51.974)65.9 (49.405 to 79.917)
Statistical analysis
  • Maintenance Phase: Placebo vs Maintenance Phase: Vedolizumab 300 mg · Cochran-Mantel-Haenszel · p = 0.0067 · Adjusted odds ratio: 3.48 · 95% CI 1.407 to 8.626CMH test was used for analysis. Prior TNFα antagonist use (yes/no) was used as stratification factor.
SecondaryPercentage of Participants With Mucosal Healing at Week 60 in Maintenance Phase

Mucosal healing is defined as a Mayo endoscopic subscore of ≤1 point. Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Endoscopic findings were scored on a scale from 0 to 3 as follows: 0=Normal or inactive disease; 1=Mild disease (erythema, decreased vascular pattern, mild friability); 2=Moderate disease (marked erythema, lack of vascular pattern, friability, erosions); 3=Severe disease (spontaneous bleeding, ulceration).

Time frame:
Week 60
Reported as:
Number · percentage of participants
Percentage of Participants With Mucosal Healing at Week 60 in Maintenance Phase
percentage of participantsMaintenance Phase: PlaceboMaintenance Phase: Vedolizumab 300 mg
Percentage of Participants With Mucosal Healing at Week 60 in Maintenance Phase33.3 (19.567 to 49.549)63.4 (46.936 to 77.877)
Statistical analysis
  • Maintenance Phase: Placebo vs Maintenance Phase: Vedolizumab 300 mg · Cochran-Mantel-Haenszel · p = 0.0066 · Adjusted odds ratio: 3.49 · 95% CI 1.409 to 8.642CMH test was used for analysis. Prior TNFα antagonist use (yes/no) was used as stratification factor.
SecondaryPercentage of Participants With Durable Remission in Maintenance Phase

Durable clinical remission is defined as complete Mayo score of ≤2 points and no individual subscore \>1 point at both Weeks 10 and 60. Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).

Time frame:
Weeks 10 and 60
Reported as:
Number · percentage of participants
Percentage of Participants With Durable Remission in Maintenance Phase
percentage of participantsMaintenance Phase: PlaceboMaintenance Phase: Vedolizumab 300 mg
Percentage of Participants With Durable Remission in Maintenance Phase16.7 (6.974 to 31.364)26.8 (14.221 to 42.944)
Statistical analysis
  • Maintenance Phase: Placebo vs Maintenance Phase: Vedolizumab 300 mg · Cochran-Mantel-Haenszel · p = 0.2090 · Adjusted odds ratio: 2.02 · 95% CI 0.677 to 6.033CMH test was used for analysis. Prior TNFα antagonist use (yes/no) was used as stratification factor.
SecondaryPercentage of Participants With Corticosteroid-Free Remission at Week 60 in Maintenance Phase

Clinical Remission is defined as a complete Mayo score of ≤2 points and no individual subscore \>1 point. Corticosteroid-free clinical remission is defined as participants using oral corticosteroids at baseline (Week 0) who discontinued corticosteroids and were in clinical remission at Week 60. Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).

Time frame:
Week 60
Reported as:
Number · percentage of participants
Percentage of Participants With Corticosteroid-Free Remission at Week 60 in Maintenance Phase
percentage of participantsMaintenance Phase: PlaceboMaintenance Phase: Vedolizumab 300 mg
Percentage of Participants With Corticosteroid-Free Remission at Week 60 in Maintenance Phase20.0 (4.331 to 48.089)46.2 (19.223 to 74.865)
Statistical analysis
  • Maintenance Phase: Placebo vs Maintenance Phase: Vedolizumab 300 mg · Cochran-Mantel-Haenszel · p = 0.1571 · Adjusted odds ratio: 3.38 · 95% CI 0.636 to 17.981CMH test was used for analysis. Prior TNFα antagonist use (yes/no) was used as stratification factor.
SecondarySerum Vedolizumab Concentration in Induction Phase
Time frame:
Pre-dose at Weeks 2, 6, 10 and 14
Reported as:
Mean · μg/mL
Serum Vedolizumab Concentration in Induction Phase
μg/mLInduction Phase: Cohort 1, Vedolizumab 300 mgInduction Phase: Cohort 2, Vedolizumab 300 mg
Week 231.93 ± 9.061733.96 ± 7.7002
Week 629.58 ± 12.96531.53 ± 12.937
Week 1031.42 ± 14.46236.63 ± 16.058
Week 1416.09 ± 7.362419.04 ± 6.6528
SecondarySerum Vedolizumab Concentration in Maintenance Phase
Time frame:
Pre-dose at Weeks 2, 6, 10, 14, 22, 30 and 60
Reported as:
Mean · μg/mL
Serum Vedolizumab Concentration in Maintenance Phase
μg/mLMaintenance Phase: PlaceboMaintenance Phase: Vedolizumab 300 mg
Week 232.87 ± 9.872934.92 ± 7.3732
Week 632.80 ± 12.95335.87 ± 11.983
Week 1039.21 ± 15.07641.02 ± 11.955
Week 1416.05 ± 7.422417.31 ± 7.1914
Week 222.913 ± 2.324314.45 ± 6.0327
Week 300.2200 ± 0.4814613.77 ± 6.3692
Week 600.000 ± 0.000021.16 ± 8.9078
SecondaryNumber of Participants With Anti-vedolizumab Antibodies (AVA) in Induction Phase

Blood samples were collected and tested for serum concentration of anti-vedolizumab antibodies in a laboratory by means of electrochemoluminescent (ECL) assay.

Time frame:
Weeks 0, 10 and 16 weeks after the last dose of study drug (Up to approximately 170 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Anti-vedolizumab Antibodies (AVA) in Induction Phase
ParticipantsInduction Phase: Cohort 1, Vedolizumab 300 mgInduction Phase: Cohort 2, Vedolizumab 300 mg
Week 000
Week 1010
16 Weeks After Last Administration11
SecondaryNumber of Participants With Anti-vedolizumab Antibodies (AVA) in Maintenance Phase

Blood samples were collected and tested for serum concentration of anti-vedolizumab antibodies in a laboratory by means of ECL assay.

Time frame:
Weeks 0, 10, 30, 60 and 16 weeks after the last dose of study drug (Up to approximately 170 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Anti-vedolizumab Antibodies (AVA) in Maintenance Phase
ParticipantsMaintenance Phase: PlaceboMaintenance Phase: Vedolizumab 300 mg
Week 000
Week 1000
Week 3040
Week 6010
16 Weeks After Last Administration00
SecondaryNumber of Participants With Neutralizing Anti-vedolizumab Antibodies (AVA) in Induction Phase

Blood samples were collected, and serum neutralizing AVA was determined only for the AVA-positive samples in a laboratory by means of ECL assay.

Time frame:
Weeks 0, 10 and 16 weeks after the last dose of study drug (Up to approximately 170 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Neutralizing Anti-vedolizumab Antibodies (AVA) in Induction Phase
ParticipantsInduction Phase: Cohort 1, Vedolizumab 300 mgInduction Phase: Cohort 2, Vedolizumab 300 mg
Week 000
Week 1010
16 Weeks After Last Administration11
SecondaryNumber of Participants With Neutralizing Anti-vedolizumab Antibodies (AVA) in Maintenance Phase

Blood samples were collected, and serum neutralizing AVA was determined only for the AVA-positive samples in a laboratory by means of ECL assay.

Time frame:
Weeks 0, 10, 30, 60 and 16 weeks after the last dose of study drug (Up to approximately 170 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Neutralizing Anti-vedolizumab Antibodies (AVA) in Maintenance Phase
ParticipantsMaintenance Phase: PlaceboMaintenance Phase: Vedolizumab 300 mg
Week 000
Week 1000
Week 3030
Week 6000
16 Weeks After Last Administration00

Adverse events

Collected over From Baseline to 16 weeks after the last dose of study drug (Up to approximately 170 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Induction Phase: Cohort 1, Placebo0/82 (0%)4/82 (4.9%)10/82 (12.2%)
Induction Phase: Cohort 1, Vedolizumab 300 mg0/164 (0%)10/164 (6.1%)28/164 (17.1%)
Induction Phase: Cohort 2, Vedolizumab 300 mg0/46 (0%)6/46 (13%)15/46 (32.6%)
Maintenance Phase: Placebo0/42 (0%)3/42 (7.1%)17/42 (40.5%)
Maintenance Phase: Vedolizumab 300 mg0/41 (0%)4/41 (9.8%)27/41 (65.9%)
Maintenance Phase: Placebo Continuation0/26 (0%)1/26 (3.8%)13/26 (50%)
Open-Label Cohort: Vedolizumab 300 mg0/259 (0%)48/259 (18.5%)191/259 (73.7%)
Most frequent serious events
Showing 10 of 51
Most frequent serious events
EventInduction Phase: Cohort 1, PlaceboInduction Phase: Cohort 1, Vedolizumab 300 mgInduction Phase: Cohort 2, Vedolizumab 300 mgMaintenance Phase: PlaceboMaintenance Phase: Vedolizumab 300 mgMaintenance Phase: Placebo ContinuationOpen-Label Cohort: Vedolizumab 300 mg
Colitis ulcerativeGastrointestinal disorders2/826/1644/462/422/410/2625/259
DehydrationMetabolism and nutrition disorders0/820/1642/460/420/410/261/259
Enterocolitis bacterialInfections and infestations0/820/1640/461/420/411/260/259
PyrexiaGeneral disorders0/820/1640/460/421/410/260/259
AppendicitisInfections and infestations0/820/1640/460/421/410/262/259
ArthralgiaMusculoskeletal and connective tissue disorders0/820/1640/460/421/410/260/259
MyalgiaMusculoskeletal and connective tissue disorders0/820/1640/460/421/410/260/259
EndometriosisReproductive system and breast disorders0/820/1640/461/420/410/260/259
Granulomatous dermatitisSkin and subcutaneous tissue disorders0/820/1640/461/420/410/260/259
Diabetes mellitusMetabolism and nutrition disorders0/820/1641/460/420/410/260/259
Most frequent other events
Showing 10 of 19
Most frequent other events
EventInduction Phase: Cohort 1, PlaceboInduction Phase: Cohort 1, Vedolizumab 300 mgInduction Phase: Cohort 2, Vedolizumab 300 mgMaintenance Phase: PlaceboMaintenance Phase: Vedolizumab 300 mgMaintenance Phase: Placebo ContinuationOpen-Label Cohort: Vedolizumab 300 mg
Viral upper respiratory tract infectionInfections and infestations8/8223/16412/469/4218/418/26130/259
Dental cariesGastrointestinal disorders0/820/1640/460/424/410/260/259
Colitis ulcerativeGastrointestinal disorders0/820/1640/464/420/411/2618/259
InfluenzaInfections and infestations0/820/1640/460/420/410/2624/259
HeadacheNervous system disorders2/826/1643/461/422/412/2623/259
Back painMusculoskeletal and connective tissue disorders0/820/1640/460/420/410/2622/259
White blood cell count decreasedInvestigations0/820/1640/462/422/412/260/259
Upper respiratory tract infectionInfections and infestations0/820/1640/461/420/412/2619/259
HaemorrhoidsGastrointestinal disorders0/820/1640/460/420/412/260/259
VomitingGastrointestinal disorders0/820/1640/461/423/411/260/259

Baseline characteristics

All participants who entered in the induction phase.

Age, Continuous
Age, Continuous(years)Induction Phase: Cohort 1, PlaceboInduction Phase: Cohort 1, Vedolizumab 300 mgInduction Phase: Cohort 2, Vedolizumab 300 mgTotal
Mean44.0 ± 15.9742.3 ± 14.4242.4 ± 15.6042.8 ± 15.02
Sex: Female, Male
Sex: Female, Male(Participants)Induction Phase: Cohort 1, PlaceboInduction Phase: Cohort 1, Vedolizumab 300 mgInduction Phase: Cohort 2, Vedolizumab 300 mgTotal
Female276520112
Male559926180
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Induction Phase: Cohort 1, PlaceboInduction Phase: Cohort 1, Vedolizumab 300 mgInduction Phase: Cohort 2, Vedolizumab 300 mgTotal
Count of participants———0
Region of Enrollment
Region of Enrollment(Participants)Induction Phase: Cohort 1, PlaceboInduction Phase: Cohort 1, Vedolizumab 300 mgInduction Phase: Cohort 2, Vedolizumab 300 mgTotal
Japan8216446292
Weight
Weight(kg)Induction Phase: Cohort 1, PlaceboInduction Phase: Cohort 1, Vedolizumab 300 mgInduction Phase: Cohort 2, Vedolizumab 300 mgTotal
Mean60.36 ± 12.41158.58 ± 11.64057.74 ± 10.55958.95 ± 11.699
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Induction Phase: Cohort 1, PlaceboInduction Phase: Cohort 1, Vedolizumab 300 mgInduction Phase: Cohort 2, Vedolizumab 300 mgTotal
Mean21.76 ± 3.66021.72 ± 3.41121.12 ± 2.71421.64 ± 3.382
Smoking Classification
Smoking Classification(Participants)Induction Phase: Cohort 1, PlaceboInduction Phase: Cohort 1, Vedolizumab 300 mgInduction Phase: Cohort 2, Vedolizumab 300 mgTotal
Never smoked448523152
Current smoker39517
Ex-smoker357018123
Duration of Ulcerative Colitis (UC)
Duration of Ulcerative Colitis (UC)(years)Induction Phase: Cohort 1, PlaceboInduction Phase: Cohort 1, Vedolizumab 300 mgInduction Phase: Cohort 2, Vedolizumab 300 mgTotal
Mean8.57 ± 7.9737.23 ± 6.2309.19 ± 7.7257.91 ± 7.022

3 further baseline measures are reported on the registry.

08

Study locations

59 sites
  • Kasugai-shi, Aichi, Japan
  • Nagoya-shi, Aichi, Japan
  • Toyota-shi, Aichi, Japan
  • Hirosaki-shi, Aomori, Japan
  • Sakura-shi, Chiba, Japan
  • Matsuyama-shi, Ehime, Japan
  • Fukui-shi, Fukui, Japan
  • Chikushino-shi, Fukuoka, Japan
  • Fukuoka-shi, Fukuoka, Japan
  • Kitakyushu-shi, Fukuoka, Japan
  • Kurume-shi, Fukuoka, Japan
  • Fukuyama-shi, Hiroshima, Japan
  • Hatsukaichi-shi, Hiroshima, Japan
  • Hiroshima-shi, Hiroshima, Japan
  • Asahikawa-shi, Hokkaido, Japan
  • Hakodate-shi, Hokkaido, Japan
  • Sapporo-shi, Hokkaido, Japan
  • Tomakomai-shi, Hokkaido, Japan
  • Akashi-shi, Hyogo, Japan
  • Himeji-shi, Hyogo, Japan
  • Itami-shi, Hyogo, Japan
  • Kobe-shi, Hyogo, Japan
  • Nishinomiya-shi, Hyogo, Japan
  • Komatsu-shi, Ishikawa, Japan
  • Marukame-shi, Kagawa, Japan
  • Takamatsu-shi, Kagawa, Japan
  • Kagoshima-shi, Kagoshima, Japan
  • Fujisawa-shi, Kanagawa, Japan
  • Kamakura-shi, Kanagawa, Japan
  • Kawasaki-shi, Kanagawa, Japan
  • Sagamihara-shi, Kanagawa, Japan
  • Yokohama-shi, Kanagawa, Japan
  • Kochi-shi, Kochi, Japan
  • Kumamoto-shi, Kumamoto, Japan
  • Kyoto-shi, Kyoto, Japan
  • Sendai-shi, Miyagi, Japan
  • Nagasaki-shi, Nagasaki, Japan
  • Beppu-shi, Ohita, Japan
  • Oita, Ohita, Japan
  • Okayama-shi, Okayama, Japan
  • Moriguchi-shi, Osaka, Japan
  • Osaka-shi, Osaka, Japan
  • Sakai-shi, Osaka, Japan
  • Suita-shi, Osaka, Japan
  • Saga-shi, Saga, Japan
  • Tokorozawa-shi, Saitama, Japan
  • Otsu, Shiga, Japan
  • Hamamatsu-shi, Shizuoka, Japan
  • Shimotsuke-shi, Tochigi, Japan
  • Adachi-ku, Tokyo, Japan
  • Bunkyo-ku, Tokyo, Japan
  • Chiyoda-ku, Tokyo, Japan
  • Edogawa, Tokyo, Japan
  • Minato-ku, Tokyo, Japan
  • Shinagawa-ku, Tokyo, Japan
  • Shinjuku-ku, Tokyo, Japan
  • Wakayama-shi, Wakayama, Japan
  • Shunan-shi, Yamaguchi, Japan
  • Kofu-shi, Yamanashi, Japan
09

References and documents

Publications

  • Naganuma M, Watanabe K, Motoya S, Ogata H, Matsui T, Suzuki Y, Ursos L, Sakamoto S, Shikamura M, Hori T, Fernandez J, Watanabe M, Hibi T, Kanai T. Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis. J Gastroenterol Hepatol. 2022 Jan;37(1):81-88. doi: 10.1111/jgh.15667. Epub 2021 Sep 7. PubMed 34409654 ↗
  • Nagahori M, Watanabe K, Motoya S, Ogata H, Kanai T, Matsui T, Suzuki Y, Pinton P, Ursos L, Sakamoto S, Shikamura M, Hori T, Fernandez J, Hibi T, Watanabe M. Week 2 Symptomatic Response with Vedolizumab as a Predictive Factor in Japanese Anti-TNFalpha-Naive Patients with Ulcerative Colitis: A post hoc Analysis of a Randomized, Placebo-Controlled Phase 3 Trial. Digestion. 2021;102(5):742-752. doi: 10.1159/000512235. Epub 2021 Jan 15. PubMed 33454706 ↗
  • Okamoto H, Dirks NL, Rosario M, Hori T, Hibi T. Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn's disease. Intest Res. 2021 Jan;19(1):95-105. doi: 10.5217/ir.2019.09167. Epub 2020 Jul 10. PubMed 32635680 ↗
  • Motoya S, Watanabe K, Ogata H, Kanai T, Matsui T, Suzuki Y, Shikamura M, Sugiura K, Oda K, Hori T, Araki T, Watanabe M, Hibi T. Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study. PLoS One. 2019 Feb 26;14(2):e0212989. doi: 10.1371/journal.pone.0212989. eCollection 2019. Erratum In: PLoS One. 2019 Apr 11;14(4):e0215491. doi: 10.1371/journal.pone.0215491. PubMed 30807613 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2014 to primary completion in Feb 2018, 48 months.

Results were first posted in Mar 2019, 1 year after primary completion.

Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 48 months is close to that.

Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2014
First posted
Jan 17, 2014
StartActual
Feb 4, 2014
Primary completionActual
Feb 27, 2018
CompletionActual
Jun 28, 2018
Results first posted
Mar 20, 2019
Last update
Apr 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02039505
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jan 17, 2014
Start date
Feb 4, 2014
Primary completion
Feb 27, 2018
Completion
Jun 28, 2018
Results posted
Mar 20, 2019
Last update
Apr 25, 2019

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vedolizumab

Start the discussion